FDA Approval Alert: The Need-to-Know | Treosulfan/Fludarabine Injection for HSCT Conditioning in AML/MDS

In January 2025, the FDA approved treosulfan plus fludarabine as an injection prior to allogeneic hematopoietic stem cell transplantation for patients who are 1 year or older with acute myeloid leukemia or myelodysplastic syndrome.

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Article
Jan 24, 2025 3:08 PM
Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.